Your browser doesn't support javascript.
loading
Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials.
Theodosaki, Astero Maria; Tzemi, Maria; Galanis, Nikiforos; Bakopoulou, Athina; Kotsiomiti, Eleni; Aggelidou, Eleni; Kritis, Aristeidis.
Afiliação
  • Theodosaki AM; Research Methodology in Medicine and Health Sciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. asteroth.dent@gmail.com.
  • Tzemi M; Regenerative Medicine Center, Basic and Translational Research Unit (BTRU) of Special Unit for Biomedical Research and Education (BRESU), Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, 54636, Greece. asteroth.dent@gmail.com.
  • Galanis N; Postgraduate program of Research Methodology in Medicine and Health Sciences, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. asteroth.dent@gmail.com.
  • Bakopoulou A; , Thessaloniki, Greece. asteroth.dent@gmail.com.
  • Kotsiomiti E; Research Methodology in Medicine and Health Sciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Aggelidou E; Postgraduate program of Research Methodology in Medicine and Health Sciences, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Kritis A; School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Stem Cell Rev Rep ; 20(4): 938-966, 2024 May.
Article em En | MEDLINE | ID: mdl-38407793
ABSTRACT
The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received. When assessed, there was a rehabilitation of the deficit and a gain in quality of life was detected. Although the heterogeneity between the studies and the small number of patients, the administration of mesenchymal stem cells in scaffolds seems safe and effective in the regeneration of bone defects. These results pave the way for the conduction of more clinical trials, with greater number of participants, with more standardized procedures.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regeneração Óssea / Transplante de Células-Tronco Mesenquimais / Alicerces Teciduais / Células-Tronco Mesenquimais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regeneração Óssea / Transplante de Células-Tronco Mesenquimais / Alicerces Teciduais / Células-Tronco Mesenquimais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article